.png "PTC Therapeutics (NASDAQ: PTCT)")
Today, a Director at PTC Therapeutics (PTCT), Michael Schmertzler, bought shares of PTCT for $2M.
Following Michael Schmertzler’s last PTCT Buy transaction on September 26, 2016, the stock climbed by 16.4%. Following this transaction Michael Schmertzler’s holding in the company was increased by 4.71% to a total of $41.39 million.
See today’s analyst top recommended stocks >>
Currently, PTC Therapeutics has an average volume of 570.2K.
Based on 6 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $49.50, reflecting a 75.8% upside. Starting in November 2018, PTCT received 5 Buy ratings in a row. Four different firms, including Cantor Fitzgerald and Credit Suisse, currently also have a Buy rating on the stock.
In the last 30 days, insiders have sold $91.57K worth of PTCT shares and purchased $2M worth of PTCT shares. The insider sentiment on PTC Therapeutics has been negative according to 11 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
PTC Therapeutics, Inc. is a biopharmaceutical company, which focuses on the discovery, development, and commercialization of novel medicines using its expertise in RNA biology. The company’s internally discovered pipeline addresses multiple therapeutic areas, including rare disorders and oncology.
